In April 2021 the U.S. Department of Health and Human Services (HHS) issued revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (Practice Guideline).
Opioids, Opioid Use Disorder, & Overdose Prevention
Reports
Displaying 1 - 10 of 39. 10 per page. Page 1.
Advanced SearchResearch Brief
Early Changes in Waivered Clinicians and Utilization of Buprenorphine for Opioid Use Disorder After Implementation of the 2021 HHS Buprenorphine Practice Guidelines
December 2, 2022
Research Brief
Meeting Substance Use and Social Service Needs in Communities of Color
November 23, 2022
In this brief, we highlight experiences and practices from substance use treatment providers and their human services partners when serving people of color. We selected providers that focused on serving people of color, and this study was not intended to assess outcomes or effectiveness of any of the practices highlighted.
Fact Sheet
Addressing the Opioid Overdose Crisis Through Better Data: Opioids Vignette
November 23, 2022
This updated 2022 vignette provides examples of how a range of Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) cross-agency projects are working to address the opioid overdose crisis by 1) Improving Timeliness and Quality of Outcomes Data 2) Building Capacity for Collection of Patient-Reported Outcomes 3) Building Linkages to Address Co-Morbidities
ASPE Issue Brief
National and State Estimates of Children Living with Parents Using Substances, 2015–2019
November 14, 2022
This brief presents estimates of the number and percentage of children whose parents engage in problematic substance use, including past-year substance use and SUD by substance type and child demographics. Key findings include:
Report
Certified Community Behavioral Health Clinics (CCBHC) Demonstration Program
November 3, 2022
Per Section 223(d)(7)(A) of the Protecting Access to Medicare Act (PAMA) of 2014 (Public Law 113-93), the HHS Secretary must submit to Congress an annual report on the use of funds provided under all demonstration programs conducted under this subsection, not later than one year after the date on which the first state is selected for a demonstration program under this subsection, and annually t
ASPE Issue Brief, Database, Dataset
Flexibilities in Controlled Substances Prescribing and Dispensing During the COVID-19 Pandemic
September 8, 2022
The COVID-19 pandemic had wide-ranging impacts on health care delivery, particularly services that require in-person interactions. For patients needing access to medications to treat pain or certain substance use disorders, the COVID-19 pandemic presented particular challenges for continuity of treatment.
Report
Opioid Use in Long-Term Care Settings: Final Report
August 9, 2022
Opioid use was very common among the long-term care (LTC) residents in our sample. Perhaps reflecting their post-acute rehabilitative needs, discharged residents were more likely to have opioid use prior to LTC admission and at the beginning of the LTC stay.
Report
Integrating SUD and OB/GYN Care: Policy Challenges and Opportunities Final Report
February 3, 2022
This report aims to address the treatment care models for pregnant and postpartum women with SUD by describing opportunities to integrate OB/GYN and SUD care as well as barriers to integrated care delivery.
ASPE Issue Brief
Integrating OB/GYN and SUD Care Policy Challenges and Opportunities Issue Brief
February 3, 2022
This brief highlights specific policy challenges and opportunities for policymakers to expand access to integrated services for pregnant and postpartum women with SUD.
ASPE Issue Brief
U.S. Department of Health and Human Services Overdose Prevention Strategy
October 27, 2021
From 1999 through 2019, there were more than 840,000 drug overdose deaths in the United States. The crisis has continually evolved and escalated, including during the COVID-19 pandemic, when an estimated 93,000 persons lost their lives to drug overdose in 2020--approximately a 30% increase over the year prior.